| 1. |
Roboz J. Epigenetic targeting and personalized approaches for AML. Hematology Am Soc Hematol Educ Program, 2014(1): 44-51.
|
| 2. |
Abdel-Wahab O, Levine L. Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia. Blood, 2013, 121(18): 3563-3572.
|
| 3. |
Saunthararajah Y. Key clinical observations after 5-azacytidine and decitabine treatment of myelodysplastic syndromes suggest practical solutions for better outcomes. Hematology Am Soc Hematol Educ Program, 2013, 2013: 511-521.
|
| 4. |
Oez S, Raddatz G, Rius M, et al. Quantitative determination of decitabine incorporation into DNA and its effect on mutation rates in human cancer cells. Nucleic Acids Res, 2014, 42(19): e152.
|
| 5. |
Cashen AF, Schiller GJ, O’donnell MR. Multicenter, phase Ⅱ study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. J Clin Oncol, 2010, 28(4): 556-561.
|
| 6. |
Lübbert M, Rüter H, Claus R, et al. A multicenter phase Ⅱ trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy. Haematologica, 2012, 97(3): 393-401.
|
| 7. |
Blum W, Garzon R, Klisovic B, et al. Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci USA, 2010, 107(16): 7473-7478.
|
| 8. |
Momparler RL, Côté S, Momparler LF, et al. Epigenetic therapy of acute myeloid leukemia using 5-aza-2’-deoxycytidine (decitabine) in combination with inhibitors of histone methylation and deacetylation. Clin Epigenetics, 2014, 6(1): 19.
|
